Literature DB >> 28451413

A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy.

Koichi Nishimura1, Toshio Takagi1, Naohiro Toda1, Tomoko Yamamoto2, Tsunenori Kondo1, Hideki Ishida1, Yoji Nagashima2, Kazunari Tanabe1.   

Abstract

Targeted medications for metastatic adult Xp11.2 translocation renal cell carcinoma (RCC) remain to be identified. We herein report a case of metastatic Xp11.2 translocation RCC controlled with cytoreductive nephrectomy (CN) and axitinib therapy. A 57-year-old woman complained of fatigue and low back pain. Imaging studies revealed a right renal tumor, with multiple lung and mediastinal lymph node metastases. Although the patient received 10 mg axitinib therapy for 5 months at the hospital she was initially admitted to, the size of the primary and metastatic lesions was not reduced. Thus, she was referred to the Tokyo Women's Medical University Hospital (Tokyo, Japan) for further treatment, where she underwent CN. On macroscopic examination, almost the entire kidney was replaced by a yellowish brown tumor >80 mm in diameter. Immunohistochemical examination confirmed the diagnosis of Xp11.2 translocation RCC. One month after surgery, axitinib therapy was resumed and the size of the metastatic lesions gradually decreased. These findings suggest that axitinib therapy is effective for adult Xp11.2 translocation RCC.

Entities:  

Keywords:  metastasis; molecular-targeted therapy; nephrectomy; renal cell carcinoma

Year:  2017        PMID: 28451413      PMCID: PMC5403318          DOI: 10.3892/mco.2017.1142

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  17 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

3.  Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: possible Xp11.2 translocation.

Authors:  Henry B Armah; Anil V Parwani
Journal:  Pathology       Date:  2008-04       Impact factor: 5.306

4.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Authors:  G G Malouf; P Camparo; S Oudard; G Schleiermacher; C Theodore; A Rustine; J Dutcher; B Billemont; O Rixe; E Bompas; A Guillot; L Boccon-Gibod; J Couturier; V Molinié; B Escudier
Journal:  Ann Oncol       Date:  2010-02-12       Impact factor: 32.976

5.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager.

Authors:  Helene Sudour-Bonnange; Xavier Leroy; Marie-Pierre Chauvet; Marion Classe; P M Robin; Pierre Leblond
Journal:  Pediatr Blood Cancer       Date:  2014-03-03       Impact factor: 3.167

7.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Authors:  Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri
Journal:  Eur Urol       Date:  2014-06-13       Impact factor: 20.096

8.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Authors:  Masumi Tsuda; Ian J Davis; Pedram Argani; Neerav Shukla; Gael G McGill; Makoto Nagai; Tsuyoshi Saito; Marick Laé; David E Fisher; Marc Ladanyi
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

10.  Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

Authors:  Simon L Conti; I-Chun Thomas; Judith C Hagedorn; Benjamin I Chung; Glenn M Chertow; Todd H Wagner; James D Brooks; Sandy Srinivas; John T Leppert
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

View more
  1 in total

1.  Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.

Authors:  Yuqing Wu; Saisai Chen; Minhao Zhang; Kuangzheng Liu; Jibo Jing; Kehao Pan; Lihua Zhang; Bin Xu; Xiaoming Lu; Ming Chen
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.